Bank of New York Mellon
TRAX

Bank of New York Mellon’s First Tracks Biotherapeutics TRAX Stock Holding History

Bank of New York Mellon’s Portfolio TRAX Stock Details TRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.4M Buy
+69,813
New +$1.31M ﹤0.01% 3158

Other funds holding TRAX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
FEG
Financial Enhancement Group Anderson, Indiana $839M AUM 18.63% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $91.8B AUM 38.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Bank of New York Mellon's TRAX Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in First Tracks Biotherapeutics (TRAX) in Q2 2026: 69,813 shares worth $1.4M. The stake represents ﹤0.01% of the portfolio and ranks #3158 among its holdings.

65 funds tracked by Wall St. Rank hold TRAX as of Q2 2026.

  • Bank of New York Mellon held 69,813 shares of First Tracks Biotherapeutics worth $1.4M as of Q2 2026.
  • First Tracks Biotherapeutics was a new Bank of New York Mellon position in Q2 2026.
  • First Tracks Biotherapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3158 holding.
  • 65 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.